NBL-CY01-P is an engineered cytokine therapy designed to stimulate angiogenesis and reduce inflammation in ischemic vascular diseases. By enhancing Type II cytokine targeted downstream pathways, this novel biologic promotes blood vessel growth and tissue repair without the need for cell transplantation. As an off-the-shelf injectable, NBL-CY01-P offers a scalable, cell-free alternative for treating conditions such as PAD, diabetic ulcers, and myocardial ischemia.